- Home
- DSGN vs DMB Comparison
DSGN vs DMB Comparison
Compare DSGN & DMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- DMB
- Stock Information
- Founded
- DSGN 2017
- DMB 2013
- Country
- DSGN United States
- DMB United States
- Employees
- DSGN N/A
- DMB N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- DMB Trusts Except Educational Religious and Charitable
- Sector
- DSGN Health Care
- DMB Finance
- Exchange
- DSGN Nasdaq
- DMB Nasdaq
- Market Cap
- DSGN 348.2M
- DMB 197.7M
- IPO Year
- DSGN 2021
- DMB N/A
- Fundamental
- Price
- DSGN $4.10
- DMB N/A
- Analyst Decision
- DSGN Hold
- DMB
- Analyst Count
- DSGN 3
- DMB 0
- Target Price
- DSGN $7.00
- DMB N/A
- AVG Volume (30 Days)
- DSGN 222.7K
- DMB 76.6K
- Earning Date
- DSGN 11-07-2024
- DMB 01-01-0001
- Dividend Yield
- DSGN N/A
- DMB 4.17%
- EPS Growth
- DSGN N/A
- DMB N/A
- EPS
- DSGN N/A
- DMB N/A
- Revenue
- DSGN N/A
- DMB N/A
- Revenue This Year
- DSGN N/A
- DMB N/A
- Revenue Next Year
- DSGN N/A
- DMB N/A
- P/E Ratio
- DSGN N/A
- DMB N/A
- Revenue Growth
- DSGN N/A
- DMB N/A
- 52 Week Low
- DSGN $2.25
- DMB $8.94
- 52 Week High
- DSGN $7.77
- DMB $11.79
- Technical
- Relative Strength Index (RSI)
- DSGN 27.98
- DMB 33.55
- Support Level
- DSGN $3.71
- DMB $10.19
- Resistance Level
- DSGN $6.81
- DMB $10.47
- Average True Range (ATR)
- DSGN 0.46
- DMB 0.11
- MACD
- DSGN -0.27
- DMB 0.00
- Stochastic Oscillator
- DSGN 10.00
- DMB 33.33
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.